Stocks to sell

Finding the best pharma stocks to sell can be an all-or-nothing kind of business. If you score on a company making a breakthrough in a new drug or treatment, the rewards can be extreme, but investing in pharma stocks can also mean heavy expenditures on research and testing for a drug that may not perform

If Novavax (NASDAQ:NVAX) stock investors are looking for a shot in the arm, they’re going to be disappointed. Even Novavax’s management expressed doubts regarding the company’s ability to continue long term. Like it or not, the evidence overwhelmingly suggests that it’s not a wise move to take a share position in Novavax. Let’s face it. Covid-19

Among cannabis stocks, SNDL (NASDAQ:SNDL) has been one that screens well as a value play. Even though this Canada-based integrated cannabis company isn’t cheap on a price-to-earnings basis, SNDL stock has for quite some time traded at a discount to its tangible book value. But investors who have bought it based on its low valuation

There’s a long-term shift in the automotive industry toward electric vehicles. However, not all players in the industry will be winners. In fact, there are quite a few EV stocks to sell, as the industry is full of companies that came public over the past few years with little track record of success or commercial

After a wretched 2022, tech stocks are rebounding nicely this year. The tech-heavy Nasdaq composite is up nearly 14% since Jan. 1, better than the Dow Jones Industrial Average and the S&P 500. And we’re nowhere near the top of this run higher. If you consider the Nasdaq composite a rough indicator of tech stocks,

It’s fine to seek out low-priced tech stocks, but I definitely do not recommend Exela Technologies (NASDAQ:XELA) stock. Exela Technologies has financial problems and the company’s shares are at risk of being delisted from the Nasdaq exchange. So, there’s too much risk to justify an investment in Exela Technologies. Headquartered in Texas, Exela Technologies specializes in business

The investor exodus out of Bed Bath & Beyond (NASDAQ:BBBY) has accelerated in recent weeks. Over the past month alone, BBBY stock has tumbled to the tune of 75.2%. This rapid move lower may be piquing the interest of bottom-fishers. After all, couldn’t an ounce of improvement with the distressed home goods retailer’s prospects pave the way

The search for yield has become even more pressing for income investors, and as inflation outpaces many of the payouts on offer, the list of dividend stocks to sell is getting larger. Of course, dividends aren’t the only way investors can make money—share price growth is another factor to consider as well. However, some shares are out

Mullen Automotive (NASDAQ:MULN) stock is once again making headlines, but these latest developments aren’t being met with much excitement based on recent price action. In the past few weeks, this early-stage electric vehicle manufacturer has hit a major milestone. The company has closed on a large financing deal. Shares have barely budged on this news.

In this volatile market, many investors are flocking to the relative security of dividend stocks. But as with any investment, you must perform your due diligence particularly when it comes to a stock’s dividend yield. In many cases, a high yield can make a dividend stock a good buy. But in some cases, a high

It’s been 19 months since Trump Media and Technology Group (TMTG) and Digital World Acquisition (NASDAQ:DWAC) announced they were merging to form a media colossus to gather subscribers for its Truth Social stock social media platform. Along the way, the DWAC shot would hit an all-time high of $101.87 on March 2, 2022. Unfortunately, it’s been

So, it’s settled: Canadian cannabis producer Tilray (NASDAQ:TLRY) plans to acquire rival Hexo (NASDAQ:HEXO). It’s debatable, however, whether this is actually a good idea. In the same press release, Tilray disclosed its financial results for the third quarter of fiscal 2023. Suffice it to say, the data doesn’t look promising, and it’s not a good

You just never know what Vinco Ventures (NASDAQ:BBIG) might do next. The company is truly unpredictable, but Vinco Ventures’ adventurous spirit won’t be enough to save BBIG stock. Don’t be too surprised if Vinco Ventures ends up on an over-the-counter (OTC) exchange at some point. I’ll admit that Vinco Ventures is full of interesting business ideas.

This hasn’t been a good year for EV stocks.  While the future is certainly electric, EV makers have had a difficult time dealing with the China lockdown and supply chain issues. The EV bubble may not burst anytime soon but a lot of companies could end up losing money.  Many EV stocks have taken a

The three most popular hedge fund stocks to avoid have more going for them than people seem to believe. Hedge funds hold considerable sway over financial markets. At the end of 2022, the world’s 15,000 hedge funds collectively managed about $4.5 trillion in assets for clients. In the North America, there are now more than

You’ve probably heard the saying, “Don’t fight the Fed” (referring to the U.S. Federal Reserve). Well, you might end up fighting the Fed if you hold Ally Financial (NYSE:ALLY) stock. Tight lending conditions definitely don’t favor Ally and the company’s investors. Don’t get the wrong idea here. Ally isn’t in imminent danger of collapsing like SVB Financial

While focusing on equities with upside potential tends to be the superior long-term option due to the U.S. capital market’s upward bias, good investors can’t avoid the topic of stocks to sell. Invariably, in this investing game, you’re going to pick a few clunkers – we all do. What separates successful players from those who

Artificial intelligence (AI) has been the talk of the town this year, and it seems like everyone is looking to get in on the action. The opportunity in AI is massive, with the market expected to be worth over $1.5 trillion by 2030. However, investors must sift the gems from the rubble and understand which

Before you jump into a hasty trade with Silvergate Capital (NYSE:SI) stock, think carefully and consider the risks involved. Silvergate Capital is an unsuccessful bank that may be in its final stages of existence. Plus, it appears that regulators are cracking down on failing banks, and this doesn’t bode well for Silvergate Capital. Based in California,

Sorry to be the bearer of bad news, but Design Therapeutics (NASDAQ:DSGN) has good intentions and less-than-stellar financials. Design Therapeutics may be a pioneer in the field of genomic medicine, and that’s commendable. Yet, DSGN stock is still likely to lose value in 2023 and might even be delisted someday. Based in California, Design Therapeutics develops